You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company plans to ship more than 1.3 million tests per month worldwide as production capacity increases in May.
Novacyt has initially committed to supply 288,000 tests per week to the DHSC, and it has an option to expand the agreement.
The test is designed for the detection of nucleic acid from SARS-CoV-2 in nasopharyngeal, oropharyngeal, nasal, and mid-turbinate nasal swab specimens as well as sputum.
The firm is looking into options for partnerships to bring a COVID-19 serology test to market, which could leverage its large installed base of instruments.
The two UK companies are validating GeneFirst's assay for use with Rapid Dx's Rapid Minilab RT-PCR Desktop Point of Care Platform.
Emergency testing related to the SARS-CoV-2 pandemic strongly increased, but routine testing declined due to fewer regular health checks.
The test was already authorized for use in Canada and South Korea. Seegene has sold more than 10 million of the assay in more than 60 countries.
Several labs and at least one company have been working on assays that add samples directly to the PCR reaction and don't require RNA extraction, a time-consuming step.
Fosun Pharma said its kit detects novel coronavirus RNA targeting the ORF1ab, N, and E genes, and it can test 96 samples within two hours.
Aria Diagnostics said the test collection kits it is supplying to New York City will help ease supply chain issues that have hampered testing.